Skip to content
ImaginAb Logo ImaginAb Logo
  • ABOUT
    • Management Team
    • Board of Directors
    • Science Advisory Board
    • Investors
    • International Operations
  • TECHNOLOGY
    • Our Approach
    • Presentations
  • 89Zr-Df-IAB22M2C
    • Product Request
  • PROGRAMS
    • Pipeline
    • Immuno-oncology
  • PRESS & MEDIA
    • Press Releases
    • Publications
    • Conferences & Events
    • Information Center
    • Video Media
  • CAREERS
    • Overview
    • Current Openings
  • CONTACT

Information Center

Information Centeradmin2020-02-25T19:47:10+00:00

Clinical Trials

89Zr-Df-IAB22M2C – CD8 ImmunoPET Tracer

IAB-CD8-201

A Phase II, Open-Label, Multi-Dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Selected to Receive Standard-of-Care Immunotherapy as Single Agent or in Combination

CONTACT US

423 Hindry Ave. Suite D Inglewood, CA 90301

Phone: +1.310.645.1211

Fax: +1.888.395.3370

ImaginAb MiniBody
ImaginAb

EMAIL US

General Inquiries:
info@imaginab.com

Commercial Inquiries:
busdev@imaginab.com

© Copyright    |   ALL RIGHTS RESERVED
FacebookTwitterLinkedIn
Go to Top